Skip to content

A comparative study of ciprofol versus propofol in gastroenteroscopy in overweight or obese patients: a randomized controlled study

A comparative study of ciprofol versus propofol in gastroenteroscopy in overweight or obese patients: a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087170
Enrollment
Unknown
Registered
2024-07-22
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Sponsors

The Seventh Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 70 years old, inclusive; 2) Patients undergoing elective painless gastroscopy or colonoscopy or gastroenteroscopy; 3) American Society of Anesthesiologists (ASA) physical status I–II; 4) Body mass index (BMI) >= 24kg/m2; 5) The operation time is expected to be no more than 60min; 6) Clearly understand and voluntarily participate in the study, and have their own or their family members sign informed consent..

Exclusion criteria

Exclusion criteria: 1. Complex endoscopic diagnosis and treatment techniques needed (such as cholangiopancreatography, endoscopic mucosal resection, endoscopic submucosal dissection, and oral endoscopic muscle dissection, etc.); 2. Patients planning to be intubated; 3. Patients to be intubatedwith SpO2 = 180mmHg and/or diastolic blood pressure>=110mmHg upon entry into the endoscopy room; 7. With respiratory insufficiency, history of obstructive lung disease; with uncontrolled clinically significant liver, kidney, hematologic, neurologic, or metabolic diseases as judged by the investigator to be unsuitable for participation in the study; 8. Pregnant or lactating women; 9. Known allergies to eggs, soy products, opioid drugs and their rescue medications, propofol, etc.; 10. History of alcohol abuse within the past 3 months, defined as daily average alcohol consumption >2 units of alcohol (1 unit = 360mL beer or 45mL 40% alcohol by volume liquor or 150mL wine); 11. Patients with craniocerebral injury, possible history of convulsion, myoclonus, intracranial hypertension, cerebral aneurysm, cerebrovascular accident; 12. Patients with schizophrenia, intellectual disability, mania, insanity, long-term use of psychotropic drugs, drug addiction, cognitive dysfunction, etc.; 13. Deemed unsuitable for participation in this trial by the investigator.

Design outcomes

Primary

MeasureTime frame
the incidence of SpO2<90%;

Secondary

MeasureTime frame
the incidence of SpO2<95%;the incidence of SpO2<75%;the incidence of SpO2<60%;Rescue measures;Induction times;recovery times;injection pain;hypotension;

Countries

China

Contacts

Public ContactJiaxin Chen

The Seventh Affiliated Hospital of Sun Yat-Sen University

chenjx326@mail.sysu.edu.cn+86 158 0001 3715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026